Temsirolimus in Relapsed and/or Refractory Mantle Cell Lymphoma†: Profile Report

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.3, 2011-06, pp. : 193-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Romidepsin in the Treatment of T-Cell Lymphoma†: Profile Report

By Yang Lily P.H.

BioDrugs, Vol. 25, Iss. 6, 2011-12 ,pp. : 393-395

Adis International

Access to resources Recommend Favorite

Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease

By Visser Otto J.

BioDrugs, Vol. 20, Iss. 4, 2006-01 ,pp. : 201-207

Adis International

Access to resources Recommend Favorite

Management of Refractory Early-Stage Cutaneous T-Cell Lymphoma

By Huber Margit A.

American Journal of Clinical Dermatology, Vol. 7, Iss. 3, 2006-01 ,pp. : 155-169

Adis International

Access to resources Recommend Favorite

Spotlight on Lenalidomide in Relapsed or RefractoryMultiple Myeloma†

By Scott Lesley J. Lyseng-Williamson Katherine A.

BioDrugs, Vol. 25, Iss. 5, 2011-10 ,pp. : 333-337

Adis International

Access to resources Recommend Favorite

Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma†: Profile Report

By Croxtall Jamie D.

BioDrugs, Vol. 25, Iss. 5, 2011-10 ,pp. : 329-331

Adis International

Access to resources Recommend Favorite